# BELINDA (NCT03570892)

> Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03570892
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Novartis Pharmaceuticals
- Conditions: Non-Hodgkin Lymphoma
- Interventions: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy; Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
- Enrollment: 330
- Primary outcome: Event-free Survival (EFS) Per Blinded Independent Review Committee (BIRC) Assessment

## Indexed commentary on BELINDA so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=belinda-nct03570892